Implications of Underlying Mechanisms for the Recognition and Management of Diabetic Cardiomyopathy

Journal of the American College of Cardiology

Volumn 71, Issue 3, 2018, Pages 339-351

  Marwick, Thomas H ^a   Ritchie, Rebecca ^a   Shaw, Jonathan E ^a   Kaye, David ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

diabetes; echocardiography; heart failure; screening

Indexed keywords

ASYMPTOMATIC DISEASE; AUTONOMIC DYSFUNCTION; CARDIAC MUSCLE CELL; DIABETIC CARDIOMYOPATHY; GLYCEMIC CONTROL; HEART FAILURE; HEART MUSCLE METABOLISM; HEART VENTRICLE REMODELING; HUMAN; HYPERGLYCEMIA; INFLAMMATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCREENING TEST; DIABETES MELLITUS; DISEASE MANAGEMENT; PATHOPHYSIOLOGY;

DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; DISEASE MANAGEMENT; HEART FAILURE; HUMANS;

EID: 85044450413     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.11.019     Document Type: Review

References (93)

1. Pappachan, J.M., Varughese, G.I., Sriraman, R., Arunagirinathan, G., Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes 4 (2013), 177–189.
2. Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30 (1972), 595–602.
3. Bugger, H., Abel, E.D., Rodent models of diabetic cardiomyopathy. Dis Model Mech 2 (2009), 454–466.
4. Kannel, W.B., Hjortland, M., Castelli, W.P., Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974), 29–34.
5. Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004), 1879–1884.
6. Shah, A.D., Langenberg, C., Rapsomaniki, E., et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 3 (2015), 105–113.
7. Konduracka, E., Cieslik, G., Galicka-Latala, D., et al. Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study. Acta Diabetol 50 (2013), 597–606.
8. Jensen, M.T., Sogaard, P., Andersen, H.U., et al. Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 study. J Am Coll Cardiol Img 8 (2015), 400–410.
9. Srivastava, P.M., Calafiore, P., Macisaac, R.J., et al. Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with type 2 diabetes. Clin Sci (Lond) 114 (2008), 313–320.
10. Wai, B., Patel, S.K., Ord, M., et al. Prevalence, predictors and evolution of echocardiographically defined cardiac abnormalities in adults with type 1 diabetes: an observational cohort study. J Diabetes Complications 28 (2014), 22–28.
11. Thrainsdottir, I.S., Aspelund, T., Thorgeirsson, G., et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28 (2005), 612–616.
12. Bahrami, H., Bluemke, D.A., Kronmal, R., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51 (2008), 1775–1783.
13. Wong, C., Marwick, T.H., Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med 4 (2007), 436–443.
14. Matsue, Y., Suzuki, M., Nakamura, R., et al. Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J 75 (2011), 2833–2839.
15. Gustafsson, I., Brendorp, B., Seibaek, M., et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43 (2004), 771–777.
16. MacDonald, M.R., Petrie, M.C., Varyani, F., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29 (2008), 1377–1385.
17. Bugger, H., Abel, E.D., Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57 (2014), 660–671.
18. Huynh, K., Bernardo, B.C., McMullen, J.R., Ritchie, R.H., Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 142 (2014), 375–415.
19. Tate, M., Grieve, D.J., Ritchie, R.H., Are targeted therapies for diabetic cardiomyopathy on the horizon?. Clin Sci (Lond) 131 (2017), 897–915.
20. Tate, M., Deo, M., Cao, A.H., et al. Insulin replacement limits progression of diabetic cardiomyopathy in the low-dose streptozotocin-induced diabetic rat. Diab Vasc Dis Res 14 (2017), 423–433.
21. Iribarren, C., Karter, A.J., Go, A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001), 2668–2673.
22. Qin, C.X., Sleaby, R., Davidoff, A.J., et al. Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications. Pharmacol Res 116 (2017), 45–56.
23. Basta, G., Schmidt, A.M., De Caterina, R., Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63 (2004), 582–592.
24. Slawson, C., Copeland, R.J., Hart, G.W., O-GIcNAc signaling: a metabolic link between diabetes and cancer?. Trends Biochem Sci 35 (2010), 547–555.
25. Ma, J., Banerjee, P., Whelan, S.A., et al. Comparative proteomics reveals dysregulated mitochondrial O-GlcNAcylation in diabetic hearts. J Proteome Res 15 (2016), 2254–2264.
26. Huynh, K., Kiriazis, H., Du, X.J., et al. Coenzyme Q(10) attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 55 (2012), 1544–1553.
27. Lebeche, D., Davidoff, A.J., Hajjar, R.J., Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 5 (2008), 715–724.
28. Ritchie, R.H., Love, J.E., Huynh, K., et al. Enhanced phosphoinositide 3-kinase (p110a) activity prevents diabetes–induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 55 (2012), 3369–3381.
29. Bornfeldt, K.E., Tabas, I., Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14 (2011), 575–585.
30. Dinh, W., Fueth, R., Nickl, W., et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol, 8, 2009, 58.
31. Donath, M.Y., Shoelson, S.E., Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11 (2011), 98–107.
32. Huynh, K., Kiriazis, H., Du, X.-J., et al. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med 60 (2013), 307–317.
33. Di Carli, M.F., Bianco-Batlles, D., Landa, M.E., et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 100 (1999), 813–819.
34. Masuo, K., Rakugi, H., Ogihara, T., Esler, M.D., Lambert, G.W., Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance. Curr Diabetes Rev 6 (2010), 58–67.
35. Thomas, M.C., Type 2 diabetes and heart failure: challenges and solutions. Curr Cardiol Rev 12 (2016), 249–255.
36. Lopaschuk, G.D., Ussher, J.R., Folmes, C.D.L., Jaswal, J.S., Stanley, W.C., Myocardial fatty acid metabolism in health and disease. Physiol Rev 90 (2010), 207–258.
37. Bugger, H., Abel, E.D., Mitochondria in the diabetic heart. Cardiovasc Res 88 (2010), 229–240.
38. Battiprolu, P.K., Hojayev, B., Jiang, N., et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest 122 (2012), 1109–1118.
39. Prakoso, D., De Blasio, M.J., Qin, C., et al. Phosphoinositide 3-kinase (p110 alpha) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin Sci (Lond) 131 (2017), 1345–1360.
40. Feng, B., Chen, S., Chiu, J., George, B., Chakrabarti, S., Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab 294 (2008), E1119–E1126.
41. Ertunc, M.E., Hotamisligil, G.S., Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res 57 (2016), 2099–2114.
42. Rijzewijk, L.J., van der Meer, R.W., Smit, J.W., et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52 (2008), 1793–1799.
43. Darley-Usmar, V.M., Ball, L.E., Chatham, J.C., Protein O-linked beta-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol 52 (2012), 538–549.
44. Montaigne, D., Marechal, X., Coisne, A., et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130 (2014), 554–564.
45. Niemann, B., Chen, Y., Teschner, M., Li, L., Silber, R.-E., Rohrbach, S., Obesity induces signs of premature cardiac aging in younger patients the role of mitochondria. J Am Coll Cardiol 57 (2011), 577–585.
46. Erbas, T., Erbas, B., Kabakci, G., Aksoyek, S., Koray, Z., Gedik, O., Plasma big-endothelin levels, cardiac autonomic neuropathy, and cardiac functions in patients with insulin-dependent diabetes mellitus. Clin Cardiol 23 (2000), 259–263.
47. Kumar, R., Yong, Q.C., Thomas, C.M., Baker, K.M., Intracardiac intracellular angiotensin system in diabetes. Am J Physiol Regul Integr Comp Physiol 302 (2012), R510–R517.
48. Di Carli, M.F., Janisse, J., Grunberger, G., Ager, J., Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 41 (2003), 1387–1393.
49. Campbell, D.J., Somaratne, J.B., Jenkins, A.J., et al. Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc Diabetol, 10, 2011, 80.
50. Joshi, M.S., Berger, P.J., Kaye, D.M., Pearson, J.T., Bauer, J.A., Ritchie, R.H., Functional relevance of genetic variations of endothelial nitric oxide synthase and vascular endothelial growth factor in diabetic coronary microvessel dysfunction. Clin Exp Pharmacol Physiol 40 (2013), 253–261.
51. Mohammed, S.F., Hussain, S., Mirzoyev, S.A., Edwards, W.D., Maleszewski, J.J., Redfield, M.M., Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (2015), 550–559.
52. Fang, Z.Y., Leano, R., Marwick, T.H., Relationship between longitudinal and radial contractility in subclinical diabetic heart disease. Clin Sci (Lond) 106 (2004), 53–60.
53. Ernande, L., Bergerot, C., Girerd, N., et al. Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus. J Am Soc Echocardiogr 27 (2014), 479–488.
54. Boyer, J.K., Thanigaraj, S., Schechtman, K.B., Perez, J.E., Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol 93 (2004), 870–875.
55. From, A.M., Scott, C.G., Chen, H.H., The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 55 (2010), 300–305.
56. Holland, D.J., Marwick, T.H., Haluska, B.A., et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart 101 (2015), 1061–1066.
57. Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A., Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 (1994), 840–844.
58. Kadappu, K.K., Boyd, A., Eshoo, S., et al. Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction?. Eur Heart J Cardiovasc Imaging 13 (2012), 1016–1023.
59. van Heerebeek, L., Hamdani, N., Handoko, M.L., et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 (2008), 43–51.
60. Kusunose, K., Kwon, D.H., Motoki, H., Flamm, S.D., Marwick, T.H., Comparison of three-dimensional echocardiographic findings to those of magnetic resonance imaging for determination of left ventricular mass in patients with ischemic and non-ischemic cardiomyopathy. Am J Cardiol 112 (2013), 604–611.
61. Levelt, E., Mahmod, M., Piechnik, S.K., et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes 65 (2016), 44–52.
62. Jellis, C., Wright, J., Kennedy, D., et al. Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. Circ Cardiovasc Imaging 4 (2011), 693–702.
63. Wong, T.C., Piehler, K.M., Kang, I.A., et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35 (2014), 657–664.
64. Shimizu, I., Minamino, T., Toko, H., et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 120 (2010), 1506–1514.
65. Ernande, L., Audureau, E., Jellis, C.L., et al. Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus. J Am Coll Cardiol 70 (2017), 1704–1716.
66. Abhayaratna, W.P., Marwick, T.H., Becker, N.G., Jeffery, I.M., McGill, D.A., Smith, W.T., Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J 152 (2006), 941–948.
67. Guo, R., Nair, S., Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. Biochim Biophys Acta 1863 (2017), 2070–2077.
68. Wang, Z., Park, K., Comer, F., Hsieh-Wilson, L.C., Saudek, C.D., Hart, G.W., Site-specific GlcNAcylation of human erythrocyte proteins potential biomarker(s) for diabetes. Diabetes 58 (2009), 309–317.
69. Albers, A.R., Krichavsky, M.Z., Balady, G.J., Stress testing in patients with diabetes mellitus: diagnostic and prognostic value. Circulation 113 (2006), 583–592.
70. Andermann, A., Blancquaert, I., Beauchamp, S., Dery, V., Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 86 (2008), 317–319.
71. Young, L.H., Wackers, F.J., Chyun, D.A., et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 301 (2009), 1547–1555.
72. Newman, J.D., Schwartzbard, A.Z., Weintraub, H.S., Goldberg, I.J., Berger, J.S., Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. J Am Coll Cardiol 70 (2017), 883–893.
73. Caobelli, F., Haaf, P., Chronis, J., et al. Prognostic usefulness of cardiac stress test modalities in patients with type 2 diabetes mellitus who underwent myocardial perfusion scintigraphy (from the Basel Asymptomatic High-Risk Diabetics' Outcome Trial). Am J Cardiol 120 (2017), 1098–1103.
74. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
75. Agarwal, S.K., Chambless, L.E., Ballantyne, C.M., et al. Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. Circ Heart Fail 5 (2012), 422–429.
76. Yang, H., Negishi, K., Wang, Y., Nolan, M., Saito, M., Marwick, T.H., Echocardiographic screening for non-ischaemic stage B heart failure in the community. Eur J Heart Fail 18 (2016), 1331–1339.
77. Gawlowski, T., Stratmann, B., Stork, I., et al. Heat shock protein 27 modification is increased in the human diabetic failing heart. Horm Metab Res 41 (2009), 594–599.
78. Dempsey, P.C., Owen, N., Yates, T.E., Kingwell, B.A., Dunstan, D.W., Sitting less and moving more: improved glycaemic control for type 2 diabetes prevention and management. Curr Diab Rep, 16, 2016, 114.
79. Look, A.R.G., Wing, R.R., Bolin, P., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369 (2013), 145–154.
80. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care 39 (2016), 686–693.
81. Parry, H.M., Deshmukh, H., Levin, D., et al. Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. Circ Heart Fail 8 (2015), 236–242.
82. Yan, J., Young, M.E., Cui, L., Lopaschuk, G.D., Liao, R., Tian, R., Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 119 (2009), 2818–2828.
83. Aubert, G., Martin, O.J., Horton, J.L., et al. The Failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
84. Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
85. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
86. Kosiborod, M., Cavender, M.A., Fu, A.Z., et al. lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation 136 (2017), 249–259.
87. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ Res 107 (2010), 1058–1070.
88. Zhou, X., Ma, L., Habibi, J., et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 55 (2010), 880–888.
89. Mortensen, S.A., Rosenfeldt, F., Kumar, A., et al., for the Q-SYMBIO Study Investigators. The effect of coenzyme Q(10) on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. J Am Coll Cardiol HF 2 (2014), 641–649.
90. Smith, R.A., Murphy, M.P., Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 1201 (2010), 96–103.
91. Gray, S.P., Jha, J.C., Kennedy, K., et al. Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia 60 (2017), 927–937.
92. Olshansky, B., Sabbah, H.N., Hauptman, P.J., Colucci, W.S., Parasympathetic nervous system and heart failure: pathophysiology and potential implications for therapy. Circulation 118 (2008), 863–871.
93. Litwin, S.E., Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy?. Diabetes 62 (2013), 3329–3330.